OTHER NEWS - July 1, 1993
From Times Staff and Wire Reports
Hepatitis B Drug Tests Halted: Eli Lilly & Co. said it has suspended clinical trials of fialuridine, intended to counter the hepatitis B virus, because 20 patients in the program suffered from serious side effects. The Indianapolis-based pharmaceuticals company said the undesirable effects included liver and kidney failure and that several participants in an earlier test phase died. It said the suspension was not related to those deaths. Lilly’s stock fell 25 to $49.25 a share on the New York Stock Exchange.
